KCT0005929招募中未知
A Multicenter Prospective Open-label Single Arm Trial to Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B With a Comparison to Matched Historical Controls (ADAPT)
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •1. Willing and able to provide written informed consent prior to study entry
- •2. Age =19 years and =65 years at the time of screening
- •3. HBsAg titer <3,000 IU/mL at the time of screening
- •4. Antiviral treatment continued at least 2 years and HBeAg (-) at the time of screening
- •5. Undetectable HBV DNA level at the time of screening
- •6. Serum ALT level <80 IU/mL at the time of screening
- •7. Estimated creatinine clearance =30 ml/min (by calculation of creatinine clearance or using the CKD-EPI equation)
- •8. Ability to comply with all study requirements
排除标准
- •1) Confirmed known co-infection with HCV, HIV, or HDV
- •2) Evidence of liver cirrhosis defined as meeting any of the following criteria:
- •(1) Splenomegaly (>12 cm) assessed by ultrasound, CT, or MRI
- •(2) Fibroscan =9.0 kPa
- •(3) Platelet count <150,000/mm3
- •However, if the above criteria were satisfied at the time of antiviral treatment initiation, subjects may be eligible if they have low possibility of having liver cirrhosis with improvement in liver function by long-term antiviral treatment, following the opinion of the investigator.
- •3) Current alcohol (60g/day) or substance abuse judged by the investigator that will potentially interfere with subject compliance
- •4) Any history of clinical hepatic decompensation (e.g., ascites, encephalopathy, variceal hemorrhage) within 12 months prior to the screening or Child-Pugh score of =7 at the time of screening
- •5) Currently on or have received therapy with Interferon or immunosuppressant (including systemic chemotherapy) within 12 months prior to the screening
- •6) Requirement for chronic use of systemic immunosuppressant including, but not limited to, corticosteroid (prednisone equivalent of >40 mg/day for >2 weeks), azathioprine, or monoclonal antibodies
- •7) Received solid organ or bone marrow transplant
- •8) Any other clinical conditions (cardiovascular, respiratory, neurologic, or renal conditions) or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
- •9) History or current evidence of hepatocellular carcinoma (HCC), or high a-fetoprotein (AFP) > 20 ng/mL. (But, the patients with AFP > 20 ng/mL can be enrolled and there is no evidence of HCC by dynamic CT or MRI perfomred within 4 months prior to the screening)
- •10) Malignancy other than hepatocellular carcinoma within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (within 2 years prior to screening with confirmation of no evidence of disease). Subjects under evaluation for possible malignancy are not eligible.
- •11) Concurrent enrollment in another clinical study for other type of antiviral treatment for CHB or immune modulatory drug within 3 months prior to Screening, participation to an observational (non-interventional) clinical studies or interventional studies not using anti-HBV or immune modulatory drugs, or during the follow-up period of an interventional study are not exclusion criteria.
- •12) Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
研究者
相似试验
已完成
4 期
The primary purpose of this study is to evaluate the post-marketingsafety of ImbruvicaTM (ibrutinib capsule 140 milligram [mg]) underactual conditions of use, and to understand the incidence ofadverse events (AEs) (serious and non-serious AEs).CTRI/2019/04/018710Johnson and Johnson Private Limited75
进行中（未招募）
2 期
Mifepristone 50 mg as a weekly contraceptivePrevention of unwanted pregnancyPregnancy and ChildbirthISRCTN29802260Women on Waves949
进行中（未招募）
1 期
Mifepristone 50 mg as weekly contraceptiveprevent pregnancyEUCTR2020-002355-38-Outside-EU/EEAwomen on web international foundation
已完成
4 期
A prospective, multicentre, open-label, single armobservational study of Concor® treatment in Asian patientswith Essential HypertensioCTRI/2010/091/002813Merck Pte Ltd3 International Business Park #02-01Nordic European CentreSingapore 6099271,000
已完成
3 期
Trial to evaluate 3mg dose of Covid Vaccine of Cadila healthcare LimitedCTRI/2021/10/037137Cadila Healthcare Limited3,000